Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Publikationen 2009


  • Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, Engert A, Einsele H, Müller-Hermelink K, Wilhelm M. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas. Results of a prospective multicenter study. J Clin Oncol, Jan 27(1):106-13 (2009)
  • Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with Non Hodgkin-Lymphoma receiving chemotherapy. Leukemia & Lymphoma Mar;50(3):374-379 (2009)
  • Klimm B, Engert A. Combined Modality Treatment of Hodgkin’s Lymphoma. Cancer J 15(2):143-9 (2009)
  • Marková J, Kobe C, Skopalova M, Klaskova K, Dedeckova K, Plütschow A, Eich H, Dietlein M, Engert A, Kozak T. FDG-PET for assessment of early treatment response after 4 cycles of chemotherapy in patients with advanced-stage Hodgkin Lymphoma has a high negative predictive value. Ann Oncol, Jul;20(7):1270-4 (2009)
  • Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey M, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Recombinant human erythropoiesis-stimulating factors and mortality in cancer patients: patient-level meta-analysis of randomised trials. Lancet, May 2;373(9674):1532-42 (2009)
  • Engert A, Eichenauer D, Dreyling M. Hodgkin Lymphoma - ESMO clinical recommendiations for diagnosis, treatment and follow-up. ESMO Guidelines. Ann Oncol, May 20(Suppl.4):108-9 (2009)
  • Reiners KS, Gossmann A, Pogge von Strandmann E, Böll B, Engert A, Borchmann P. Brief Communication: Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin Lymphoma. J Immunother Jun;32(5):508-12 (2009)
  • Engert A, Diehl V, Franklin J, Lohri A, Dörker B, Ludwig WD, Koch P, Hänel M, Mohren M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Dühmke E, Müller-Hermelink HK, Hasenclever D, Löffler M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkins Lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol Sept 20;27 (27):4548-4554 (2009)
  • Böll B, Eltaib F, Reiners KS, von Tresckow B, Tawadros S, Simhadri VR, Burrows FJ, Lundgren K, Hansen HP, Engert A, Pogge von Strandmann E. Heat Shock Protein 90 Inhibitor BIIB021 (CNF2024) depletes NF-kB and sensitizes Hodgkins’s Lymphoma cells for natural killer cel-mediated cytotoxicity. Clin Can Res Aug 15(16):5108-5116 (2009)
  • Vahdat AM, Reiners KS, Simhadri VL, Eichenauer DA, Böll B, Chalaris A, Simhadri VR, Wiegmann K, Krell HW, Rose-John S, Engert A, Pogge von Strandmann E, Hansen HP.  TNF-?-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive osygen species. Leukemia Nov 5 (2009) [Epub ahead of print]  -Leukemia 24:51-57 (2010)
  • Eichenauer DA, Bredenfeld H, Haverkamp H, Müller H, Franklin J, Fuchs M, Borchmann P, Müller-Hermelink HK, Eich HT, Müller RP, Diehl V, Engert A. Hodgkin lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin Study Group (GHSG). J Clin Oncol Dec 27(20): 6079-85 (2009)
  • Böll B, Borchmann P, Topp MS, Hänel M, Reiner KS, Engert A, Naumann R. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol Oct 15 (2009) [Epub ahead of print]
  • Engert A, del Giglio A, Bias P, Lubenau H, Gatzemeier U. Heigener D. Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer and non Hodgkin’s lymphoma. Onkologie Oct;32(10):599-604 (2009)
  • Pels H, Juergens A, Glasmacher A, Schulz H, Engert A, Linnebank M, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Lamprecht M, Hau P, Deckert M, Fimmers R, Bangard C, Schmidt-Wolf I, Schlegel U. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol Feb;91(3):299-305 (2009)
  • Flechtner H, Markova J, Borchmann P, Engert A. Quality of life in long-term survivors from Hodgkins disease. Leukemia & Lymphoma 17(4):61-70 (2009)


  • Hagenbeek A, Gascoyne RD, Dreyling M, Kluin P, Engert A, Salles G. Biomarkers and prognosis in malignant lympomas. Clin Lymphoma Myeloma, Apr 9(2):160-9 (2009)
  • Eichenauer DA, Engert A. Recent advances in the treatment of early-stage Hodgkin’s Lymphoma. Hematology education: the education program for the annual congress of the European Hematology Association 3(1):151-154 (2009)
  • Elter T, Vehreschild J, Gribben J, Cornely OA, Engert A, Hallek M. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hemal 88:121-132 (2009)
  • Eichenauer D, Engert A, Schulz H. Expanded use of rituximab in the management of non-Hodgkin lymphoma.  OncoTargets and Therapy 2:189-197 (2009) 
  • Engert A. Diagnostik und Therapie des Hodgkin Lymphoms. Im Focus Onkologie 10: 77-80 (2009) 
  • Herbst C, Rehan FA, Brillant C, Bohlius J, Skoetz N, Schulz H, Monsef I, Specht L, Engert A. Combined modality treatment improves tumour control and overall survival in patients with early stage Hodgkin lymphoma: a systematic review. Haematologica Nov 30 (2009) [Epub ahead of print]
  • Eichenauer DA, Engert A. Is there a role for BEACOPP in relapsed Hodgkin Lymphoma? Leukemia & Lymphoma 50(11):1733-1734 (2009)
  • Herbst C, Naumann F, Kruse EB, Monsef I, Bohlius J, Schulz H, Engert A. Prophylactic antibiotics or G-CSF fort he prevention of infections and improvement of survival in cancer patients undergoing chemotherapy (review). Cochrane Database Syst Rev, Jan 21(1) (2009) 
  • Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke MJ, Weingart O, Kluge S, Piper M, Napoli M, Rades D, Steensma D, Djulbegovic B, Fey MF, Ray-Coquard I, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Erythropoietin or Darbepoetin for patients with cancer – meta-analysis based on individual patient data (review). Cochrane Database Syst Rev, Jul 8(3) (2009)
  • Bauer K, Skoetz N, Brillant C, Herbst C, Monsef I, Kluge S, Engert A. Tenth Biannual Report of the Cochrane Haematological  Malignancies Group – Focus on Acute Myeloid Leukemia. J Natl Cancer Inst, Oct 21,101:E1 (2009)
  • Klimm B, Engert A. Combined Modality Treatment of Hodgkin’s Lymphoma. Cancer J 15(2):143-9 (2009)
  • Skoetz N, Weingart O, Monsef I, Bauer K, Brillant C, Herbst C, Kluge S, Engert A. Ninth biannual report of the Cochrane Haematological Malignancies Group – Focus on Hematopoietic Growth Factors. J Natl Can Inst 101(9):E1, 2009 [Epub ahead of print]
  • Elter T, Kilp J, Borchmann P, Schulz H, Hallek M, Engert A. Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Haematologica Jan;94(1):150-2 (2009)